Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price target cut by stock analysts at Needham & Company LLC from $24.00 to $22.00 in a research note issued on Friday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 27.02% from the stock’s previous close.

Several other research analysts also recently commented on the company. ValuEngine downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 11th. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 15th. Finally, BidaskClub raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, June 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average price target of $21.00.

NASDAQ AMPH traded up $0.14 during mid-day trading on Friday, hitting $17.32. The stock had a trading volume of 147,896 shares, compared to its average volume of 136,294. Amphastar Pharmaceuticals has a twelve month low of $14.40 and a twelve month high of $20.45. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.53 and a current ratio of 1.94. The company has a market cap of $800.83 million, a P/E ratio of 114.53, a P/E/G ratio of 2.57 and a beta of 1.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 8th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The firm had revenue of $71.00 million during the quarter, compared to analyst estimates of $64.22 million. During the same period in the prior year, the company posted $0.11 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. sell-side analysts predict that Amphastar Pharmaceuticals will post 0.24 EPS for the current fiscal year.

In related news, CEO Jack Y. Zhang bought 25,000 shares of the company’s stock in a transaction on Tuesday, May 15th. The stock was bought at an average cost of $16.08 per share, for a total transaction of $402,000.00. Following the acquisition, the chief executive officer now directly owns 2,065,619 shares in the company, valued at $33,215,153.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael A. Zasloff sold 15,000 shares of the company’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $16.52, for a total value of $247,800.00. Following the completion of the sale, the director now owns 29,845 shares of the company’s stock, valued at $493,039.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,649 shares of company stock valued at $542,766. 31.50% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of AMPH. Piedmont Investment Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $128,000. Meeder Asset Management Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 259.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock worth $160,000 after purchasing an additional 7,572 shares during the period. SG Americas Securities LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $161,000. Renaissance Technologies LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth $227,000. Finally, A.R.T. Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 1st quarter worth $318,000. Institutional investors own 43.55% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Story: Penny Stocks, What You Need To Know

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.